IGF-DES vs Ipamorelin

N-terminal truncation eliminates IGFBP binding, leaving nearly all circulating IGF-DES unbound and active. Results in substantially higher tissue IGF-1R activation versus native IGF-1 at equivalent doses. Activates PI3K/Akt/mTOR for muscle hypertrophy and satellite cell proliferation.

A truncated form of IGF-1 with the first 3 amino acids removed. Does not bind IGF binding proteins (IGFBPs), resulting in dramatically higher free active concentration at tissue level. Considered highly anabolic with limited systemic safety data in humans.

Ipamorelin binds to the ghrelin receptor (GHSR-1a) and stimulates dose-dependent GH release with a clean hormonal profile. Unlike GHRP-6 or hexarelin, it does not significantly stimulate appetite-related pathways or cortisol secretion at standard research doses. This selectivity makes it a frequently studied peptide for protocols where hormonal side-effect profiles are a consideration.

Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist. It stimulates pulsatile GH release from the anterior pituitary with high selectivity — producing minimal effect on cortisol, prolactin, or ACTH compared to earlier GHRPs. It is commonly researched for its role in supporting body composition, recovery, and lean mass maintenance.